Chemical Structure
Wedelolactone [524-12-9]
AG-CN2-0424
Overview
- SupplierAdipoGen Life Sciences
- Product NameWedelolactone
- Delivery Days Customer10
- CAS Number524-12-9
- CertificationResearch Use Only
- Estimated Purity>98%
- Hazard InformationWarning
- Molecular FormulaC16H10O7
- Molecular Weight314.2
- Scientific DescriptionCell permeable, selective and irreversible IKKalpha and beta kinase activity inhibitor [2]. NF-kappaB inhibitor. Blocks phosphorylation and degradation of IkappaBalpha [2]. Antihepatotoxic. 5-Lipoxygenase (5-LOX) inhibitor [1, 2]. Anti-inflammatory [2]. HIV-1 integrase inhibitor [3]. Anticancer and antiproliferative compound [4, 5]. Modulates androgen receptor (AR) activation [4]. Apoptosis inducer via downregulation of PKCepsilon [5, 9]. DNA topoisomerase IIalpha inhibitor [6]. G protein-coupled receptor-35 (GPR35) agonist [7]. Inhibits adipogenic differentiation of mesenchymal stem cells (hAMSCs) through ERK pathway [8]. STAT1 protein dephosphorylation inhibitor [10]. Antifibrotic [11]. - Chemical. CAS: 524-12-9. Formula: C16H10O7. MW: 314.2. Isolated from Eclipta prostrata. Cell permeable, selective and irreversible IKKalpha and beta kinase activity inhibitor. NF-kappaB inhibitor. Blocks phosphorylation and degradation of IkappaBalpha. Antihepatotoxic. 5-Lipoxygenase (5-LOX) inhibitor. Anti-inflammatory. HIV-1 integrase inhibitor. Anticancer and antiproliferative compound. Modulates androgen receptor (AR) activation. Apoptosis inducer via downregulation of PKCepsilon. DNA topoisomerase IIalpha inhibitor. G protein-coupled receptor-35 (GPR35) agonist. Inhibits adipogenic differentiation of mesenchymal stem cells (hAMSCs) through ERK pathway. STAT1 protein dephosphorylation inhibitor. Antifibrotic.
- SMILESCOC1=CC(O)=C2C3=C(C4=C(O3)C=C(O)C(O)=C4)C(=O)OC2=C1
- Storage Instruction-20°C,2°C to 8°C
- UNSPSC12352200
References
- Wedelolactone and coumestan derivatives as new antihepatotoxic and antiphlogistic principles: S.M. Wong, et al.; Arzneimittelforschung 38, 661 (1988)
- Wedelolactone suppresses LPS-induced caspase-11 expression by directly inhibiting the IKK complex: M. Kobori, et al.; Cell Death Differ. 11, 123 (2004)
- HIV-1 protease and HIV-1 integrase inhibitory substances from Eclipta prostrata: S. Tewtrakul, et al.; Phytother. Res. 21, 1092 (2007)
- Compounds from Wedelia chinensis synergistically suppress androgen activity and growth in prostate cancer cells: F.M. Lin, et al.; Carcinogenesis 28, 2521 (2007)
- Pharmacologic inhibitors of IkappaB kinase suppress growth and migration of mammary carcinosarcoma cells in vitro and prevent osteolytic bone metastasis in vivo: A.I. Idris, et al.; Mol. Cancer Ther. 8, 2339 (2009)
- Inhibition of topoisomerase IIalpha: novel function of wedelolactone: P. Benes, et al.; Cancer Lett. 303, 29 (2011)
- Anti-inflammatory gallic Acid and wedelolactone are G protein-coupled receptor-35 agonists: H. Deng & Y. Fang; Pharmacology 89, 211 (2012)
- Wedelolactone inhibits adipogenesis through the ERK pathway in human adipose tissue-derived mesenchymal stem cells: S. Lim, et al.; J. Cell Biochem. 113, 3436 (2012)
- Wedelolactone, a medicinal plant-derived coumestan, induces caspase-dependent apoptosis in prostate cancer cells via downregulation of PKCepsilon without inhibiting Akt: S. Sarveswaran, et al.; Int. J. Oncol. 41, 2191 (2012)
- Wedelolactone, a naturally occurring coumestan, enhances interferon-gamma signaling through inhibiting STAT1 protein dephosphorylation: Z. Chen, et al.; J. Biol. Chem. 288, 14417 (2013)